2023 AGM Webinar Presentation

Chairman Osagie Imasogie and CEO Dr Oludare Odumosu deliver the AGM presentation

Investor Webinar: Top line trial results of Zelira’s diabetic nerve pain drug vs Lyrica®

Osagie Imasogie (Chairman) and Oludare Odumosu (Global CEO) take investors and analysts through the top line comparative trial results of Zelira’s diabetic nerve pain drug vs Lyrica® including efficacy, safety and next steps for the organisation.

Investor Webinar: HOPE<sup>®</sup> 1 SPV created to fund Ph.2 and Ph.3 US FDA trials

Chairman Osagie Imasogie and CEO Oludare Odumosu lead a presentation on the creation of an SPV and US $8.6M cornerstone funding from Cantheon Capital LLC for HOPE 1 Ph.2 and Ph.3 US FDA clinical trials.

Hannam and Partners Investor Report – Zelira completes enrolment in Diabetic Nerve Pain trial

H&P’s updated report on Zelira highlighted by the completed enrolment of participants in the diabetic nerve pain trial

Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Oludare Odumosu present a company update at the 2022 Annual General Meeting.

Zelira Global CEO Oludare Odumosu provides Proactive with an update on the company’s progress with its proprietary revenue-generating products, global expansion and its pipeline of candidates undergoing clinical development.

Hannam and Partners Investor Report – Zelira Therapeutics Oct 2022

Hannam and Partners Investor Report completed October 2022 provides an updated analysis of Zelira Therapeutics highlighting exciting, recently announced developments in their Rx and tech vertical

Hear the latest business updates from Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu.

Hannam and Partners Investor Report – Zelira Therapeutics July 2022

Hannam and Partners investor report completed July 2022 provides and update and overview of Zelira Therapeutics following German regulatory approval and lists a target share price of $11.70

  • 1
  • 2
  • 6

Start typing and press Enter to search

Shopping Cart